Al-Mekhlafi A, Becker T, Klawonn F Sample size and performance estimation for biomarker combinations based on pilot studies with small sample sizes. Communications in Statistics-Theory and Methods. 2020; 1-15
Hanna GB, Boshier PR, Markar SR, Romano A Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis. JAMA Oncol. 2019 Jan 1;5(1):e182815. doi: 10.1001/jamaoncol.2018.2815. Epub 2019 Jan 10. Erratum In: JAMA Oncol. 2019 Jul 1;5(7):1070.
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020 Jun;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011. Epub 2020 Mar 30.
Murchison AG, Moreland JA, Gleeson F Incidental findings in a referral pathway for non-specific cancer symptoms. Clin Imaging. 2021 Sep;77:9-12. doi: 10.1016/j.clinimag.2021.01.042. Epub 2021 Feb 17.
Nicholson BD, Hamilton W, Koshiaris C, Oke JL, Hobbs FDR, Aveyard P The association between unexpected weight loss and cancer diagnosis in primary care: a matched cohort analysis of 65,000 presentations. Br J Cancer. 2020 Jun;122(12):1848-1856. doi: 10.1038/s41416-020-0829-3. Epub 2020 Apr 15.
Pearson C, Poirier V, Fitzgerald K, Rubin G, Hamilton W Cross-sectional study using primary care and cancer registration data to investigate patients with cancer presenting with non-specific symptoms. BMJ Open. 2020 Jan 10;10(1):e033008. doi: 10.1136/bmjopen-2019-033008.
Pepe MS, Li CI, Feng Z Improving the quality of biomarker discovery research: the right samples and enough of them. Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):944-50. doi: 10.1158/1055-9965.EPI-14-1227. Epub 2015 Apr 2.
Sud A, Turnbull C, Houlston R Will polygenic risk scores for cancer ever be clinically useful? NPJ Precis Oncol. 2021 May 21;5(1):40. doi: 10.1038/s41698-021-00176-1. No abstract available.
Vasilakis C, Forte P Setting up a rapid diagnostic clinic for patients with vague symptoms of cancer: a mixed method process evaluation study. BMC Health Serv Res. 2021 Apr 17;21(1):357. doi: 10.1186/s12913-021-06360-0.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
